Evonik Industries AG (ETR:EVK)
Market Cap | 7.38B |
Revenue (ttm) | 14.71B |
Net Income (ttm) | 424.00M |
Shares Out | 466.00M |
EPS (ttm) | 0.92 |
PE Ratio | 17.31 |
Forward PE | 12.59 |
Dividend | 1.17 (7.30%) |
Ex-Dividend Date | May 29, 2025 |
Volume | 1,324,307 |
Average Volume | 870,109 |
Open | 16.00 |
Previous Close | 16.02 |
Day's Range | 15.80 - 16.07 |
52-Week Range | 15.81 - 22.39 |
Beta | 0.91 |
RSI | 34.42 |
Earnings Date | Nov 4, 2025 |
About Evonik Industries AG
Evonik Industries AG produces and sells specialty chemicals in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America. It operates through Specialty Additives, Nutrition & Care, Smart Materials, and Technology & Infrastructure segments. The Specialty Additives segment offers additives for polyurethane foams; additives, matting agents, fumed silicas, and specialty resins for paints, coatings, and printing inks; isophorone and epoxy curing agents for coatings, adhesives, and composites; and pour-point depr... [Read more]
Financial Performance
Financial StatementsNews
Look Beyond The Volatility In Evonik Industries

EQS-DD: Evonik Industries AG: Dr. Claudine Mollenkopf, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.08.2025 / 10:16 CET/CEST The issuer is solely responsi...

EQS-DD: Evonik Industries AG: Thomas Wessel, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.08.2025 / 10:09 CET/CEST The issuer is solely responsi...

EQS-PVR: Evonik Industries AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evonik Industries AG Evonik Industries AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide ...
Evonik Industries reports Q2 results
Evonik Industries AG (EVKIF) Q2 2025 Earnings Call Transcript
Evonik Industries AG 2025 Q2 - Results - Earnings Call Presentation

EQS-PVR: Evonik Industries AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evonik Industries AG Evonik Industries AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide ...

EQS-AFR: Evonik Industries AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Evonik Industries AG / Preliminary announcement on the disclosure of financial statements Evonik Industries AG: Preliminary announcement of the publicat...

EQS-DD: Evonik Industries AG: Christian Kullmann, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.06.2025 / 11:18 CET/CEST The issuer is solely responsi...

EQS-DD: Evonik Industries AG: Dr. Claudine Mollenkopf, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 03.06.2025 / 10:46 CET/CEST The issuer is solely responsi...
Evonik Industries AG (EVKIF) Q1 2025 Earnings Call Transcript
Evonik Industries AG (OTCPK:EVKIF) Q1 2025 Results Conference Call May 12, 2025 5:00 AM ETCompany ParticipantsChristian Kullmann - Chairman of the Executive...
Evonik Industries reports Q1 results
Evonik: Decent Rate Of Return, Upside Confirmed
Evonik Industries AG (EVKIF) Q4 2024 Earnings Call Transcript
Evonik Industries reports Q4 results; initiates Q1 and FY25 outlook
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven can...

EQS-News: Feasibility Study with Evonik Confirms LEON’s FR-JET Technology’s Performance in Advanced Nanoparticle Manufacturing for Drug Delivery
EQS-News: leon-nanodrugs GmbH / Key word(s): Study results Feasibility Study with Evonik Confirms LEON’s FR-JET Technology’s Performance in Advanced Nanoparticle Manufacturing for Drug Delivery 05.12....
Evonik: A Good Company, Upside Less Clear Than Before

EQS-DD: Evonik Industries AG: Dr. Cornelius Baur, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 26.11.2024 / 10:25 CET/CEST The issuer is solely responsi...
Evonik opens new Care Solutions Innovation lab in Thane
Evonik Industries AG (EVKIF) Q3 2024 Earnings Call Transcript
Evonik Industries AG 2024 Q3 - Results - Earnings Call Presentation
Evonik Industries reports Q3 results

Agilis Unveils 'Alchemist' AI Solutions to Transform Customer Engagement in the Chemical Industry, with Evonik as Pilot Customer
Newark, New Jersey--(Newsfile Corp. - September 17, 2024) - Agilis, a leader in digital customer engagement solutions for the chemical industry, today announces the launch of Alchemist, a suite of AI-...